About

About ARTES Biotechnology GmbH ARTES Biotechnology, CDMO for pharma and life science industry Our expertise is on yeast (Hansenula, Pichia) and E. coli cell line development for recombinant biopharmaceutical products (subunit vaccines, sdAB´s, therapeutics and biosimilars), highly efficient upstream and downstream process development and manufacturing (from lab to pilot scale) as well as transfer of the technology to our customers. We are a valued partner for the pharmaceutical and life science industry. Several contract developments and technology transfers are successfully implemented worldwide at clients' sites. Our offer in a nutshell: • Development of microbial expression cell lines from yeast (Hansenula, Pichia) and bacteria (E. coli) • Development of up- and downstream processes and the optimization • nonGMP manufacturing • protein analytics • transfer of the developed or optimized strains and processes to customer’s plant including support until implementation of the process • transfer of in-house developed cell lines or production processes (technology transfer) • sales of antigens, recombinant enzymes and functional proteins as lab reagents Our proprietary technologies have resulted in innovative products marketed worldwide. There are WHO recommendation, worldwide registrations and approvals at EMA resp. FDA and GRAS certification for enzymes. This all is part of the track record achieved in international collaborations. You are invited to have a closer look at: www.artes-biotechnology.com